- Home
- AMIX vs XBIO Comparison
AMIX vs XBIO Comparison
Compare AMIX & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMIX
- XBIO
- Stock Information
- Founded
- AMIX 2014
- XBIO N/A
- Country
- AMIX United States
- XBIO United States
- Employees
- AMIX N/A
- XBIO N/A
- Industry
- AMIX
- XBIO Biotechnology: Pharmaceutical Preparations
- Sector
- AMIX
- XBIO Health Care
- Exchange
- AMIX NYSE
- XBIO Nasdaq
- Market Cap
- AMIX 7.3M
- XBIO 6.3M
- IPO Year
- AMIX N/A
- XBIO N/A
- Fundamental
- Price
- AMIX $3.46
- XBIO $3.98
- Analyst Decision
- AMIX
- XBIO Hold
- Analyst Count
- AMIX 0
- XBIO 1
- Target Price
- AMIX N/A
- XBIO N/A
- AVG Volume (30 Days)
- AMIX 188.6K
- XBIO 24.1K
- Earning Date
- AMIX 02-11-2025
- XBIO 11-12-2024
- Dividend Yield
- AMIX N/A
- XBIO N/A
- EPS Growth
- AMIX N/A
- XBIO N/A
- EPS
- AMIX N/A
- XBIO N/A
- Revenue
- AMIX N/A
- XBIO $2,523,427.00
- Revenue This Year
- AMIX N/A
- XBIO N/A
- Revenue Next Year
- AMIX N/A
- XBIO N/A
- P/E Ratio
- AMIX N/A
- XBIO N/A
- Revenue Growth
- AMIX N/A
- XBIO 7.15
- 52 Week Low
- AMIX $2.88
- XBIO $2.78
- 52 Week High
- AMIX $152.00
- XBIO $5.20
- Technical
- Relative Strength Index (RSI)
- AMIX 34.39
- XBIO 55.58
- Support Level
- AMIX $2.88
- XBIO $3.94
- Resistance Level
- AMIX $3.60
- XBIO $4.31
- Average True Range (ATR)
- AMIX 0.33
- XBIO 0.24
- MACD
- AMIX 0.22
- XBIO -0.01
- Stochastic Oscillator
- AMIX 45.90
- XBIO 52.28
About AMIX AUTONOMIX MEDICAL INC
Autonomix Medical Inc is a development-stage medical device development company focused on advancing innovative technologies for sensing and treating disorders relating to the nervous system. Its first-in-class technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies.
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immune-oncology technologies addressing cancers. The company is also engaged in progressing XCART, a personalized CAR T platform technology. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. The company also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin-resistant endometrial cancer.